# Dr. Jessica Duncan

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/dr-jessica-duncan
Canonical HTML page: https://getbiobrief.com/entity/dr-jessica-duncan

## Timeline

- **2026-07**: FDA Advisory Panel Hearing — Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.

## Recent coverage (1 stories)

### FDA Panel Greenlights 6 of 7 Peptide Therapies, Signaling Shift in Bioregulatory Framework
2026-08-03 18:47:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Full story: https://getbiobrief.com/story/fdapanel-6-peptide-therapies-bioregulatory-shift

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.